Jabbour EJ, Haddad FG, Short NJ, Senapati J, et al. Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission. Blood 2023 Oct 25:blood.2023022330. doi: 10.1182/blood.2023022330.
PMID: 37879077